Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus

被引:2
|
作者
Petrovic, Gordana [1 ]
Pasic, Srdjan [1 ]
Soldatovic, Ivan [2 ]
机构
[1] Mother & Child Hlth Care Inst, Belgrade 11000, Serbia
[2] Univ Belgrade, Sch Med, Belgrade 11000, Serbia
关键词
pediatric rheumatology; antiphospholipid antibodies; childhood SLE; SLEDAI; ANTICARDIOLIPIN ANTIBODIES; DAMAGE; RISK;
D O I
10.3390/jcm12041424
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The aim of the study is to evaluate the effect of the presence of antiphospholipid antibodies on the clinical and laboratory manifestations, disease activity and outcomes of the disease in patients with childhood-onset systemic lupus erythematosus (cSLE). Methods: We conducted a 10-year cross-sectional study with a retrospective analysis of clinical and laboratory parameters and outcome of the disease (kidney, nervous system involvement, thrombosis). For the purpose of the study, patients were divided into cohort groups based on the presence of antiphospholipid antibodies (aPLA), named the aPLA positive group, or their absence, named the aPLA negative group. Values of aPLA were defined in reference laboratories. The disease activity was measured by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, whereas tissue damage degree was measured by Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR DI; SDI; DI). Results: Research in our center showed that patients with cSLE often had hematological, cutaneous, and non-thrombotic neurological manifestations. Antiphospholipid antibodies may be present transiently or permanently. A significant change in the titer value was observed in the IgG isotype of aCLA. The presence of higher values of IgM beta 2GP1 at the beginning indicates that higher disease activity can be expected. Higher disease activity correlates with greater tissue damage. Additionally, it has been shown that aPLA positive patients have two and a half times higher risk of tissue damage than aPLA negative ones. Conclusion: Our study shows that the presence of antiphospholipid antibodies in patients with childhood onset systemic lupus erythematosus may indicate a higher risk of tissue damage, but since it is a rare disease in childhood, prospective and multicenter studies are necessary to assess the importance of the presence of these antibodies.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies
    Harel, Liora
    Sandborg, Christy
    Lee, Tzielan
    von Scheven, Emily
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (09) : 1873 - 1877
  • [2] NEUROPSYCHIATRIC MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: PREVALENCE AND ASSOCIATION WITH ANTIPHOSPHOLIPID ANTIBODIES
    Sanna, G.
    Bertolaccini, M. L.
    Cuadrado, M. J.
    Laing, H.
    Khamashta, M. A.
    Mathieu, A.
    Hughes, G. R. V.
    RHEUMATOLOGY, 2002, 41 : 105 - 105
  • [3] Neuropsychiatric manifestations in systemic lupus erythematosus: Prevalence and association with antiphospholipid antibodies
    Sanna, G
    Bertolaccini, ML
    Cuadrado, MJ
    Laing, H
    Khamashta, MA
    Mathieu, A
    Hughes, GRV
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (05) : 985 - 992
  • [4] ANTIPHOSPHOLIPID ANTIBODIES AND LOW COMPLEMENT LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATION WITH CLINICAL MANIFESTATIONS AND PROGNOSIS
    Paglionico, A.
    Varriano, V.
    Gremese, E.
    Petricca, L.
    Gigante, M. R.
    Marino, G.
    Ferraccioli, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S32 - S32
  • [5] Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus
    Farzaneh-Far, Afshin
    Roman, Mary J.
    Lockshin, Michael D.
    Devereux, Richard B.
    Paget, Stephen A.
    Crow, Mary K.
    Davis, Adrienne
    Sammaritano, Lisa
    Levine, Daniel M.
    Salmon, Jane E.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 3918 - 3925
  • [6] Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association?
    Mehmet Sahin
    Nursen Duzgun
    Sevket Ercan Tunc
    Huseyin Tutkak
    Clinical Rheumatology, 2007, 26 : 154 - 160
  • [7] Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association?
    Sahin, Mehmet
    Duzgun, Nursen
    Tunc, Sevket Ercan
    Tutkak, Huseyin
    CLINICAL RHEUMATOLOGY, 2007, 26 (02) : 154 - 160
  • [8] The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
    Unlu, Ozan
    Zuily, Stephane
    Erkan, Doruk
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2016, 3 (02) : 75 - 84
  • [9] Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus
    Ilgen, U.
    Yayla, M. E.
    Ates, A.
    Okatan, I. E.
    Yurteri, E. U.
    Torgutalp, M.
    Kelesoglu, A. B. D.
    Turgay, T. M.
    Kinikli, G.
    LUPUS, 2018, 27 (04) : 665 - 669
  • [10] A Followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus
    Avcin, Tadej
    Benseler, Susanne M.
    Tyrrell, Pascal N.
    Cucnik, Sasa
    Silverman, Earl D.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (02): : 206 - 213